Taiwan Liposome TLC shares are trading higher on Monday.
The company announced the results of its TLCS590 Phase 2 Trial for its Postsurgical pain management demonstrated greater reduction in pain.
Cantor Fitzgerald also maintained its Overweight on the company and raised its price target from $10 to $12 per share.
Taiwan Liposome is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products based on its proprietary drug delivery technologies. The company offers products in therapeutic areas, such as oncology, PAD, ophthalmology, fungal infection, arthritis, and anesthetic indications
Taiwan Liposome shares were trading up 8.82% at $5.34 at time of publication on Monday. The stock has a 52-week high of $8.54 and a 52-week low of $2.48.
Related Links:
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
